A joint project of the Graduate School, Peabody College, and the Jean & Alexander Heard Library

Title page for ETD etd-07072015-101934


Type of Document Dissertation
Author Karolak, Matthew Ross
Author's Email Address matthew.r.karolak@vanderbilt.edu
URN etd-07072015-101934
Title Neurofibromin Regulated Signaling Pathways in Endochondral Ossification
Degree PhD
Department Pharmacology
Advisory Committee
Advisor Name Title
Joey Barnett Committee Chair
Ela Knapik Committee Member
Florent Elefteriou Committee Member
Jonathan Schoenecker Committee Member
Xiangli Yang Committee Member
Keywords
  • Dwarfism
  • FGFR1
  • NF1
  • Neurofibromatosis Type 1
  • Growth Plate
  • Chondrocyte
  • Fracture Healing
  • Neurofibromin
Date of Defense 2015-07-01
Availability unrestricted
Abstract
Neurofibromatosis type 1 (NF1) is the most common autosomal dominant genetic disorder occurring in 1 of every 3500 live births. NF1 is caused by loss-of-function mutations in NF1, the gene encoding the Ras-GAP neurofibromin. Forty percent of NF1 patients will develop orthopedic complications which often includes unilateral bowing of the extremities, fracture, and subsequent fracture healing deficits (pseudarthrosis). Because the molecular and cellular aspects mechanisms of fracture healing largely recapitulate the processes of bone development, the goal of this dissertation is to characterize the function of neurofibromin in growth plate chondrocytes and the signaling pathways it regulates during endochondral ossification. Using conditional mouse knockout models of NF1, we found that neurofibromin regulates growth plate chondrocyte proliferation, hypertrophic maturation, and matrix catabolism at the osteochondral border. Furthermore, we found that neurofibromin in prehypertrophic chondrocytes likely attenuates FGFR1 and FGFR3 signaling to inhibit chondrocyte proliferation, and neurofibromin in hypertrophic chondrocytes attenuates FGFR1 signaling to inhibit matrix catabolism as the osteochondral border. Finally, in a series of pharmacological proof-of-principle experiments, we identified C-type natriuretic peptide and the pan-FGFR inhibitor BGJ-398 as potential therapeutic agents for the treatment of NF1 pseudarthroses via their action on Nf1-/- chondrocytes. Further investigation of these agents in NF1 fracture healing models is warranted.
Files
  Filename       Size       Approximate Download Time (Hours:Minutes:Seconds) 
 
 28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access 
  Karolak.pdf 8.83 Mb 00:40:51 00:21:00 00:18:23 00:09:11 00:00:47

Browse All Available ETDs by ( Author | Department )

If you have more questions or technical problems, please Contact LITS.